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Congenital muscular dystrophies have a broad spectrum of geno-
types and phenotypes and there is a need for a better biochemical
understanding of this group of diseases in order to aid diagnosis
and treatment. Several mutations resulting in these diseases cause
reduced O-mannosyl glycosylation of glycoproteins, including
α-dystroglycan. The enzyme POMGnT1 (protein-O-mannose N-
acetylglucosaminyltransferase1;EC2.4.1.-)catalysesthetransfer
of N-acetylglucosamine to O-linked mannose of α-dystroglycan.
In the present paper we describe the biochemical characterization
of 14 clinical mutants of the glycosyltransferase POMGnT1,
which have been linked to muscle-eye-brain disease or similar
conditions. Truncated mutant variants of the human enzyme
(recombinant POMGnT1) were expressed in Escherichia coli
and screened for catalytic activity. We ﬁnd that three mutants
show some activity towards mannosylated peptide substrates
mimickingα-dystroglycan;theresiduesaffectedbythesemutants
arepredictedbyhomologymodellingtobeontheperipheryofthe
POMGnT1 surface. Only in part does the location of a previously
describedmutatedresidueontheperipheryoftheproteinstructure
correlate with a less severe disease mutant.
Keywords:congenitalmusculardystrophy,glycopeptide,muscle-
eye-brain disease, protein-O-mannose N-acetylglucosaminyl-
transferase 1 (POMGnT1).
INTRODUCTION
The cell-surface receptor α-DG (α-dystroglycan) is, alongside
β-DG (β-dystroglycan), a central component of the dystrophin–
glycoprotein complex, which connects the extracellular matrix to
the cytoskeleton. α-DG is a 650 amino acid protein containing
three distinct domains, two globular domains on the N- and
the C-termini, and a large central mucin-type domain essential
for the binding to proteins in the basal lamina, such as
laminin, agrin, biglycan, neurexin and perlecan [1–5]. The proper
glycosylation of the mucin-type domain of α-DG with O-linked
speciﬁc carbohydrates is key for maintenance of membrane
stability. The mature human α-DG glycoprotein has three
N-glycosylation sites, up to ﬁve predicted glycosaminoglycan-
attachment sites [6], and more than 50 other serine and threonine
residues which can potentially carry O-glycans. Although the
predicted protein mass is only 71 kDa, native glycosylated
α-DG migrates as a diffuse band between 120 and 250 kDa
on reducing SDS/PAGE [7,8]. Other than the mucin-like O-
glycan structures, another less common O-glycan structure,
Neu5Ac(α2,3)Gal(β1,4)GlcNAc(β1,2)Man-O,hasbeendetected
on mammalian α-DG and may play a role in the binding of α-DG
toextracellularproteinligands[9–11].Originallyregardedtobea
yeast-speciﬁcmodiﬁcation,O-mannosylationinmammalsisonly
present on a limited number of proteins in neuronal and muscular
tissue [12]. Although various O-mannose glycopeptides could be
identiﬁed from total brain tissue [13,14], α-DG still remains the
only mammalian glycoprotein clearly identiﬁed to contain this
rare modiﬁcation (Figure 1).
The essential nature of glycosylation for the function of α-DG
has been conﬁrmed by studying muscle tissue of patients with
α-dystroglycanopathies. This heterogenous group of autosomal
recessive disorders encompasses a broad spectrum of conditions,
with clinical phenotypes ranging from mild LGMD (limb-
girdle muscular dystrophy) without cognitive impairment, to
MEB (muscle-eye-brain disease) and WWS (Walker–Warburg
syndrome) with severe brain and eye abnormalities [15,16].
Immunostaining of muscle samples using the polyclonal
GT20ADG antibody raised against hypoglycosylated α-DG
showed that α-DG expression levels of α-dystroglycanopathy
patients are comparable with these of control samples [10].
In contrast, the same patient samples have reduced or absent
immunostaining with IIH6 and VIA4-1 monoclonal antibodies,
whose binding requires native glycosylation of α-DG. The loss of
glycosylation is signiﬁcant, reducing the molecular mass of the
mature protein by 50 kDa or more [17].
Molecular testing of patients with clinical signs of CMD
(congenital muscular dystrophy) revealed that mutations in
six genes encoding known or putative glycosyltransferases are
responsible for hypoglycosylation of α-DG, supposedly due
to the reduced or lost enzymatic function. The mutated
forms of the POMT1 (protein-O-mannosyltransferase 1),
POMT2 (protein-O-mannosyltransferase 2), POMGnT1 (pro-
tein O-mannose N-acetylglucosaminyltransferase 1), FKTN
(fukutin), FKRP (fukutin-related protein) and LARGE (like-
acetylglucosaminyltransferase) genes were originally reported
in patients with distinct phenotypes [18–22], and therefore
defects of those glycosyltransferases were initially associated
Abbreviations used: CK, creatine kinase; CMD, congenital muscular dystrophy; α-DG, α-dystroglycan; β-DG, β-dystroglycan; FKRP, fukutin-
related protein gene; FKTN, fukutin gene; Fmoc, ﬂuoren-9-ylmethoxycarbonyl; GnTI, N-acetylglucosaminyltransferase I; IPTG, isopropyl β-D-
thiogalactopyranoside; LARGE, like-acetylglucosaminyltransferase gene; LB, Luria–Bertani; LGMD, limb-girdle muscular dystrophy; MALDI–TOF, matrix-
assisted laser-desorption ionization–time-of-ﬂight; MEB, muscle-eye-brain disease; POMGnT1, protein-O-mannose N-acetylglucosaminyltransferase
1; POMT1, protein-O-mannosyltransferase 1; POMT2, protein-O-mannosyltransferase 2; rPOMGnT1, recombinant protein-O-mannose N-
acetylglucosaminyltransferase 1; SPSS, solid-phase peptide synthesis; WWS, Walker–Warburg syndrome.
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Figure 1 α-DG plays a key role in the formation of the dystrophin glycoprotein complex
Laminin in the basal lamina binds to O-mannose-linked carbohydrates of α-DG. In muscle cells, α-DG binds non-covalently to β-DG in the sarcolemma, which is linked to the F-actin (ﬁlamentous
actin) cytoskeleton and signalling proteins (dystrobrevin) via dystrophin. Loss of POMGnT1 function results in the truncation of the saccharide structures down to a single O-linked mannose;
clinically this loss correlates with MEB and similar conditions. The sugar phosphate modiﬁcation of the mannose residue, potentially affected by mutation of LARGE, is not shown.
with different clinical conditions. In recent years, a wider
spectrum of phenotypes with different severities have been
reported for mutations in the POMT1 [23,24], POMT2 [25,26]
and the FKTN gene [27,28], whereas mutations affecting FKRP
[29,30], POMGnT1 [31–33] and LARGE [34,35] have been
described to have less phenotypical variation. However, a
study of 81 CMD patients from Italy could only detect 43
homozygous or heterocompound mutations (53%) in those six
genes [34], which allows the presumption that even more, as
yet unidentiﬁed, genes are involved in the post-translational
modiﬁcation of α-DG.
Biochemically, POMT1, POMT2 and POMGnT1 are known
to transfer the ﬁrst two residues (mannose and GlcNAc) of the
O-mannosyl modiﬁcation [22,36]. Recently, LARGE was shown
to be involved in the phosphorylation of O-linked mannose on
α-DG [37], whereas the biochemical functions of fukutin and
FKRP are still unknown. The aim of the present study was to
characterize the enzymatic properties of 14 clinical mutations
of POMGnT1 which have been linked to MEB, LGMD and
similarconditions.Thereforeasimpleexpressionandpuriﬁcation
protocol for POMGnT1 in the prokaryotic host Escherichia coli
had to be developed; a series of mannopeptides derived from
α-DG were synthesized and tested as acceptor substrate for the
recombinant, partially puriﬁed wild-type enzyme. The optimal
substrate was then used for (i) testing recombinantly expressed
POMGnT1 mutant enzymes for activity, (ii) determining the
kinetic parameters of the active POMGnT1 variants, and (iii)
evaluating the possibility of correlating genotype with the
obtained biochemical data.
EXPERIMENTAL
Subcloning of POMGnT1 from a bacterial cDNA clone
The cDNA clone containing the complete POMGnT1 gene
was obtained from Geneservice (GenBank® accession number
BC001471). The plasmid was isolated (Qiagen Miniprep kit)
and used as a DNA template for a PCR ampliﬁcation. The
primer pair Fw (forward)/EcoRI (5
 -ACGAATTCAGTGAA-
GCCAATGAAGACCC-3
 ) and Rv (reverse)/XhoI (5
 -GACTC-
GAGCTATGTCTGTTCTGGGGCTC-3
 ) was used in combin-
ation with KOD DNA Polymerase (Roche). The primers were
designed to amplify the sequence encoding amino acids 66–
660, i.e. a form lacking the N-terminal putative transmembrane
domain. The PCR fragment was cut with the relevant enzymes
and ligated into pET30a which contains a sequence encoding an
N-terminal His tag; clones which displayed no mutation after full
sequencing of the insert were used for further experiments.
Expression and puriﬁcation of POMGnT1 mutants
Complementary oligonucleotide primers containing the desired
mutation were used to generate POMGnT1 mutant genes (see
Supplementary Table S1 at http://www.BiochemJ.org/bj/436/
bj4360447add.htm) according to the standard protocol for
QuikChange® site-directed mutagenesis (Stratagene); plasmid
DNA of transformants was sequenced to verify that selected
clones contained the desired mutation. Mutant plasmids were
transformed into E. coli BL21(DE3) competent cells (Invitrogen)
andplatedonLB(Luria–Bertani)agarplatescontaining50 μg/ml
kanamycin. Alternatively, plasmids were transformed into E. coli
ArcticExpress
TM (DE3) competent cells (Stratagene) and plated
on LB agar plates containing 50 μg/ml kanamycin and 20 μg/ml
gentamicin. For each transformed mutant, 400 ml of LB medium
(Sigma) was inoculated with 2 ml of starter culture and cells were
g r o w nt oaD600 value of 0.6. Induction was carried out with IPTG
(isopropyl β-D-thiogalactopyranoside) at a ﬁnal concentration of
500 μM, and cells were typically incubated at 13◦C for 16 h. The
cells were harvested at 4000 g for 15 min and the supernatant
discarded. The resulting cell pellet (approximately 500 mg) was
resuspended in 20 ml of lysis buffer [50 mM Tris/HCl and
500 mM NaCl (pH 8.0)] and sonicated for 20 min (20 on/off
cycles with 15 μm amplitude for 30 s at 4◦C). The lysates were
centrifuged at 24000 g for 30 min at 4◦C, the supernatant was
syringe-ﬁltered (0.45 μM pore size, Sartorius) and the resulting
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Figure 2 Native POMGnT1 in comparison with the recombinant form and
to GnT1
(a) Schematic diagram of native POMGnT1 shows an N-terminal transmembrane domain
(TM) and a C-terminal GnT-I domain (Pfam PF03071). The position of mutations introduced
are marked with a slanted cross. For expressing the recombinant protein rPOMGnT1, the
transmembrane domain was substituted with a His tag. (b) Homology model of POMGnT1
basedontheknowncrystalstructureofGnT1(PDBcode1FOA).ThemodelledC-terminalGnT-I
domain is modelled as a red solid ribbon, whereas the non-homologous N-terminal part is
displayed as a transparent ribbon loop. Inactive mutants are numbered in black, and mutants
with catalytic activity are numbered in blue. UDP-GlcNAc is shown in stick form. (c) Sequence
alignment of POMGnT1 with PDB code 1FOA using BLOSOM (default parameters = multiple
alignment gap penalty = 10.0, gap extension penalty = 0.05, open delay divergent = 40.0);
comparison of putative catalytic subunits POMGnT1 (Arg367–Thr660) and GnT1 (Lys82–Thr343)
gives a sequence identity (dark blue shading) of 33.2% and a sequence similarity (light blue
shading) of 50.3%. Single amino acid changes found in clinical mutants are marked with
blue (conserved in GnT1) and red (not conserved in GnT1) crosses; the catalytic amino acid
Asp476 ismarkedwithablackcross;themodiﬁedDXD-motif(Glu393–Asp395)isunderlinedwith
a black bar.
protein solution was loaded on to a 1 ml Ni
2+-chelation column
(HiTrap, GE Healthcare). The column was washed with 20 ml of
binding buffer [50 mM Tris/HCl, 10 mM imidazole and 500 mM
NaCl (pH 8.0)] to remove unbound proteins from the column.
The partially puriﬁed recombinant protein (rPOMGnT1; see
also Figure 2a) was eluted with 2 ml of elution buffer [50 mM
Tris/HCl, 500 mM imidazole and 500 mM NaCl (pH 8.0)], and
concentrated to 100 μl using centrifugal concentrators [Sartorius,
30 kDa MWCO (molecular mass cut-off)].
SDS/PAGE and Western blot analysis
ThepartiallypuriﬁedmutantrPOMGnT1proteinswereincubated
with SDS/PAGE buffer at 95◦C for 10 min, separated by
SDS/PAGE and visualized by Coomassie Blue staining. Protein
concentrations of the expressed mutant rPOMGnT1 ranged from
50 to 250 μg/ml, calculated by densitometric comparison with
a 70 kDa protein standard (300 μg/ml) using ImageJ analysis
software [38]. For Western blot analysis, protein gels were
transferred on to nitrocellulose using a semi-dry blotting
apparatus. After blocking with 0.5% BSA, the membranes
were incubated with horseradish peroxidase-conjugated mouse
anti-polyHistidine antibody (anti-His, 1:1000 dilution, Sigma);
after washing, recombinant protein was visualized chromogen-
ically using the SigmaFAST
TM DAB (3,3-diaminobenzidine)
reagent.
Assay of recombinant rPOMGnT1 variants
The mannopeptide acceptor substrates were derived from
the sequence of human α-DG (UniProt accession number
Q14118), a glycoprotein that plays a role in the formation of
a transmembrane link between laminin and dystrophin [39].
Sequences corresponding to serine/threonine-rich regions of the
protein were selected for SPSS (solid-phase peptide synthesis)
(see Figures 3a–3c; chemical synthesis is described in the Sup-
plementary Experimental section at http://www.BiochemJ.org/
bj/436/bj4360447add.htm).
For testing the enzymatic activity of the wild-type rPOMGnT1
variant towards the chemically synthesized acceptor substrates,
5 μl of partially puriﬁed enzyme solution was added to 5 μl
of 1 mM acceptor, 2 μl of 0.4 M Mes (pH 7), 2 μlo f0 . 2 M
MnCl2 and 6 μl of 1 mM UDP-GlcNAc, and incubated for 16 h
at 37◦C; a volume of 0.2 μl from the reaction mix was analysed
using a Voyager-DE STR MALDI–TOF (matrix-assisted laser-
desorptionionization–time-of-ﬂight)massspectrometer(Applied
Biosystems) with 2,5-dihydroxybenzoic acid as matrix.
The HPLC-based enzymatic assay for testing the activity
of the different rPOMGnT1 variants was performed with the
synthetic mannopeptide Ac-ATPT
•PVTAIG-OH (T
• indicates
the α-mannosylated threonine); in contrast with the other
mannopeptides tested, this acceptor substrate allowed, after
optimizing of the solvent gradient and the type of reverse-
phase column, baseline separation between substrate and product
peak. The different retention times of the mannopeptide
substrate and GlcNAc-mannopeptide product (17.7 and 18.5 min
respectively)couldbeachievedusingaC8 reversed-phasecolumn
(Phenomenex Sphereclone, 250 mm × 2 mm, 3 μm pore size)
withaﬂowrateof0.2 ml/min.SolventAwas0.1%triﬂuoroacetic
acid in H2O, solvent B was 0.1% triﬂuoroacetic acid in
acetonitrile. The programme used was as follows: 0–10 min,
100% solvent A; 10–40 min, linear gradient to 50% solvent
and then returning to solvent A (reconditioning for 20 min). The
elution of the glycopeptides was monitored via UV detection
at 214 nm and electrospray MS detection (Agilent System 1100
LC/MSD SL).
For the determinations of the Km values of both UDP-GlcNAc
and the mannopeptide Ac-ATPT
•PVTAIG-OH, an enzymatic
assay was performed with a series of different substrate
concentrations. For determination of the Km value of the acceptor
substrateforanactiverPOMGnT1mutant,assayswereperformed
for4 hat37◦Cusingvariableconcentrationsofthemannopeptide
(2–10 mM), and a constant UDP-GlcNAc concentration of
10 mM. After heat-inactivation at 95◦C, the reaction mixture
was analysed using the HPLC method described above. All
experiments were performed in triplicate, and the kinetic data
were calculated by using the relative peak areas corresponding to
acceptor substrate and product.
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Figure 3 Chemical synthesis of mannopeptides derived from α-DG
(a) SPPS using Fmoc-protected mannosyl serine (1a) and mannosyl threonine (1b) building blocks for the evaluation of enzyme substrates of POMGnT1. (b) Synthesized peptides corresponding
to portions of the amino acid sequence of α-DG are highlighted (grey, no enzymatic activity observed; black, enzymatic activity observed). (c) The glycoforms of the mannopeptide synthesized are
shown with the glycosylamino acids indicated with a superscript dot; those which acted as POMGnT1 acceptor substrates are shown with a tick, whereas those which did not function are shown with
a cross.
Homology modelling of POMGnT1
As the crystal structure of POMGnT1 has not yet been solved,
a homology model of POMGnT1 (UniProt accession number
Q8WZA1)wasbuiltbasedontheknowncrystalstructureofrabbit
GnTI (N-acetylglucosaminyltransferase I, UniProt accession
number P27115) encoded by the MGAT1 gene [40]. The catalytic
domains of human POMGnT1 and GnTI show 45% homology
over 159 amino acid residues [41]. All modelling was performed
using Accelrys Discovery Studio 2.0 with default parameters (cut
overhangs, no disulﬁdes, no ligands and no loop reﬁning). In
order to identify an homologous structure, a BLAST search of
the POMGnT1 amino acid sequence was performed against all
sequences in the PDB database [42]. The top hit was found to
be PDB code 1FOA, which corresponds to the catalytic fragment
of GnTI. The sequence of POMGnT1 was then aligned with the
sequence of GnTI using the ‘Align Multiple Sequences’ protocol.
The overall sequence identity was found to be 18.8% and the
sequence similarity was 33.5%. The homology model was then
generated based on the sequence alignment and structure of GnTI
using the ‘Build Homology Models’ protocol. A ﬁnal alignment
was created in which the POMGnT1 sequence was aligned with
the sequence of the homology model.
RESULTS
Human rPOMGnT1 can be expressed catalytically active in E. coli
Although the recombinant expression of POMGnT1 has been
typically performed either as a full-length protein in mammalian
cell culture [22,41], or in soluble form in insect cells, lacking the
ﬁrst 226 residues [43], our strategy was to assess the expression
capabilities of the prokaryotic host E. coli using a form lacking
the ﬁrst 65 residues. Initial experiments were performed using
transformed BL21(DE3) competent cells, the most common host
strain for protein expression. Culture samples were taken after
3, 8 and 16 h of induction with 500 μM IPTG at 16, 25 and
30◦C. The highest expression levels were observed after 8 h of
induction at 16◦C, judged by anti-His Western blot analysis.
The conditions described above were used for a puriﬁcation
experimentusingNi
2+-chelationchromatography,andtheelution
fraction analysed by Western blot showed a band migrating
between 70 and 100 kDa, indicating the soluble expression
of the recombinant rPOMGnT1 protein. Although a whole
series of activity tests were performed, which systematically
tested different mannopeptides, and substrate and metal ion
concentrations, no catalytic activity could be determined for
rPOMGnT1 expressed in BL21(DE3) cells. Therefore a new
attempt was made using ArcticExpress
TM (DE3) cells, which
are in comparison with other strains re-engineered for protein
expression at lower temperatures, thereby potentially facilitating
increased yield and activity of the recombinant protein [44].
Expressionexperimentswereperformedat13◦Cusing500 μM
IPTG and cells were harvested 16 h after induction. Anti-
His Western blot analysis of the cell lysate and from the
eluate after Ni
2+-chelation chromatography both showed a
band migrating at approximately 80 kDa, indicating soluble
expression of rPOMGnT1 (see Supplementary Figure S1 at
http://www.BiochemJ.org/bj/436/bj4360447add.htm).Incontrast
with the expression in BL21(DE3) cells, partially puriﬁed
rPOMGnT1 from ArcticExpress
TM (DE3) cells showed catalytic
activity. Activity tests with a ﬁnal concentration of 250 μMo ft h e
mannopeptideAc-ATPT
•PVTAIG-OHanda1.2-foldexcessofthe
donor substrate UDP-GlcNAc showed 20–25% conversion into
productwithin4 h.Morethan95%conversioncouldbeachieved
after 48 h of incubation.
Wild-type rPOMGnT1 was active towards some, but not all,
synthesized mannopeptides
In order to establish that peptide sequences in α-DG are indeed
substrates for POMGnT1, a library of mannopeptides was
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generated which corresponded to sequences of the mucin-like
stem region of α-DG (Figure 3b). Thus wild-type POMGnT1
was screened against a library of 21 mannopeptides produced by
SPPS,whichwasoptimizedfortheintroductionofFmoc(ﬂuoren-
9-ylmethoxycarbonyl)-protected mannosyl serine and mannosyl
threoninebuildingblocks(Figure3a).Oftheseproteinsequences,
20 where chosen according to the serine/threonine-rich sequence
of human α-DG, including three mannopeptides based on the
region surrounding Thr
319. In total, three variants corresponding
tothislatterregionwereused:(i)Ac-ATPT
•PVTAIG-OH,(ii)Ac-
ATPT
•PVTAIGP-NH2, and (iii) the modiﬁed Ac-AAPT
•PVAAP-
NH2, featuring an exchange of Thr
317 for alanine, adopted
by Takahashi et al. [45] in order to avoid modiﬁcation by
a background O-GlcNAc transferase activity and by proteases
present in brain extracts (Figure 3c). All three peptides
based on the region around Thr
319 acted as substrates in a
comparable manner; in particular, only one GlcNAc residue was
transferred and no proteolysis was observed. On the basis of this
ﬁnding, and also as E. coli is known to have no endogenous O-
GlcNAc transferase activity, the kinetic studies were performed
with the ﬁrst of these peptides, i.e. the peptide without the
threonine to alanine and C-terminal modiﬁcations.
Surprisingly, rPOMGnT1 only displayed catalytic transfer
towards six of the screened mannopeptide substrates. None of
the mannopeptides containing mannosyl serine residue were
glycosylated, and all of the positive substrates contained a
proline residue which was C-terminal of the acceptor mannosyl
threonine residue, although such sequences were also observed
in the mannopeptides which were not substrates for POMGnT1.
Moreover, small variations in the mannopeptide sequences could
affect the substrate speciﬁcity of POMGnT1. For example, for
mannosylated isomers of the H-TTTTTRRPTK-OH peptide, only
modiﬁcations in positions 2, 3 and 4 of the penta-threonine
motif, but unexpectedly not positions 1 and 5, were accepted
as substrates (Figure 3c). Nevertheless, these studies allowed
us to select a natural mannopeptide fragment of α-DG which
could be used for further kinetic studies of POMGnT1 mutant
activities.
Some rPOMGnT1 variants containing clinically relevant mutations
show in vitro activity
A number of clinically relevant POMGnT1 mutations have been
described in the literature, ranging from nonsense/frameshift
mutationstoapproximately14differentpointmutationswhichen-
code full-length proteins, as well as truncated proteins caused by
nonsense mutations within the C-terminal region [22,31–33,46–
53]. Table 1 gives an overview of homozygous and compound
heterozygous mutations described to date in the literature.
When expressed in E. coli, the 14 point-mutant variants and
the wild-type rPOMGnT1 showed similar expression levels
ranging from approx. 20 to 100 μgo fr P O M G n T 1p e rgo f
wet cell weight (Figure 4a, see also Supplementary Table S2 at
http://www.BiochemJ.org/bj/436/bj4360447add.htm). Activity
tests showed that three mutants (R265H, C269Y and D556N) still
had catalytic activity, whereas all other mutations resulted in no
activity at all. In comparison with the speciﬁc enzymatic activity
for wild-type rPOMGnT1 (25.5+ −5.8 m-units/mg), R265H
and C269Y showed a 5-fold decrease (5.3+ −1.4 and 4.4+ −0.3
m-units/mg respectively), and D556N showed a 2.5-fold decrease
(10.8+ −1.6 m-units/mg) in activity (Figures 4b–4g). Further
kineticanalysisofthewild-typeandthosethreeactivePOMGnT1
mutants showed similar Km values for UDP-GlcNAc of
between 2 and 3 mM. Thus these mutations do not seem to affect
the binding to the donor substrate. However, the Km values for
Figure 4 Clinically relevant POMGnT1 mutations of MEB patients and
activity studies of the recombinant enzyme
(a) Western blot analysis of His-tagged rPOMGnT1 mutants expressed in E. coli. Molecular
mass standards are shown on the right-hand side. (b) Assay of active rPOMGnT1 mutants
by liquid chromatography. The mannopeptide substrate Ac-ATPT•PVTAIG-OH was incubated
for 4 h with partially puriﬁed POMGnT1 wild-type and mutant enzymes in the presence of
UDP-GlcNAc. The peaks eluting at 17.7 and 18.5min were veriﬁed by MS to contain the
reaction product and substrate respectively. (c–g) Characterization of the acceptor substrate
Ac-ATPT•PVTAIG-NH2 (c) and the product after enzymatic reaction of rPOMGnT1 wild-type
(d) and mutants (e–g) by MALDI–TOF MS (see more spectra in Supplementary Figure S2 at
http://www.BiochemJ.org/bj/436/bj4360447add.htm).
the mannopeptide Ac-ATPT
•PVTAIG-OH varied from ≈6m M
for the wild-type enzyme and the D556N mutant, to >25 mM for
the mutants R265H and C269Y.
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Table 1 Description of clinically relevant POMGnT1 mutations
CK, creatine kinase measured and given in units/l (normal values in the range of 24–240 for children from 1 to 18years of age [54]); FCMD, Fukuyama CMD; f, female; m, male; nd, information is
not available for these patients.
Mutation Age (sex) 1st allele 2nd allele CK Clinical diagnosis Biopsy Reference(s)
1+9 7 S198R C490Y 1000 MEB Yes [47]
2 12 (m) E223K Phe149 frameshift 167 stop 2365 WWS or MEB nd [33]
2 8 (f) E223K Mutation in intron 17 1844 MEB or FCMD nd [33]
3 7 (f) C269Y Val328 frameshift 338 stop 852 MEB or severe FCMD nd [33]
4/5 + 7 11 month (m) R265H R442C 495 Postnatal diagnosis of hydrocephalus nd [53]
R311Q
4/5 + 7 9 (f) R265H R442C 2327 MEB nd [53]
R311Q
4/5 + 13 20 month (f) R265H R605H >3000 MEB Yes [51]
R311Q
6 17 (m) W425S Mutation in intron 21 nd MEB Yes [48,50]
7 15 months (m) R442C R442C 2697 MEB nd [32]
7 3 months (m) R442C R442C 1798 MEB nd [32]
7 14 (f) R442C R442C 724 MEB nd [32]
7 + 8 2 (m) R442C R442H 1000 MEB nd [32]
9 nd C490Y Mutation in intron 7 1000 MEB or FCMD Yes [49]
9 nd C490Y C490Y nd MEB nd [48]
10 nd (m) P493R Val262 frameshift 633 stop nd MEB Yes [22]
9 + 11 nd Trp590 stop C490Y nd MEB nd [48]
12 + 13 5 (f) Arg580 stop R605H 1953 MEB Yes [32]
13 16 (f) R605H R605H 9311 MEB Yes [46,52]
14 21 (f) D556N D556N 12000 MEB Yes [31,49]
Homology modelling suggests locations of mutations in protein
structure
POMGnT1 was ﬁrst identiﬁed as a homologue of the N-glycan-
modifying enzyme GnTI and was indeed initially named in
one study as GnTI.2 [22,41]. Sequence alignment showed that
the homology of POMGnT1 to GnTI was much higher in the
putative catalytic domain than in the N- and C- terminal regions,
a ﬁnding compatible with a previous study which delineated a
minimal catalytic region between residues 299 and 642 [43].
Using this sequence alignment, a three-dimensional model of
the putative catalytic subunit of POMGnT1 was constructed
based on the crystal structure of GnT1. The distribution of
the clinically relevant mutations in the enzyme structure was
examined (Figures 2b and 2c), and no disease-speciﬁc ‘hot-
spot’ on the protein structure was identiﬁed; some mutations
were close to the putative active site, others some distance away.
Nevertheless, Arg
265,C y s
269 and Asp
556 are predicted to be on the
periphery of the structure of the protein.
DISCUSSION
Sincethecorrelationbetweenmutationsoftheglycosyltransferase
POMGnT1 in patients with MEB was discovered almost a decade
ago [22], a continuous stream of case studies have described
more than 25 independent homozygous mutations distributed
throughout the 21 exonic regions of the POMGnT1 locus [32].
Some of the phenotypes studied widened the spectrum of the
disease caused by these mutations to the milder form of LGMD
[31], whereas other POMGnT1 mutations result in symptoms
overlapping with the more severe form of WWS [32,33]. The
14 POMGnT1 mutations analysed for catalytic activity in the
present study are derived from gene analyses described in 11
different previously published studies (see Table 1). All of these
studies showed a diverse subset of diagnostic methods for the
determination of the phenotypical ﬁndings, such as the evaluation
of psychomotoric and mental development, muscle biopsies with
immunostaining or immunoblotting, MRI (magnetic resonance
imaging),CK(creatinekinase)analysisorbiochemicalassaysfor
each patient examined. To the best of our knowledge, the present
study gives the only comprehensive biochemical evaluation of all
clinically relevant POMGnT1 point mutations known to date.
One of the open questions was whether the full loss of enzyme
activity is required for the phenotype, or if reduced activities also
have the potential for pathogenic alterations. In good correlation
with the genotypes observed, we show that three out of the 14
mutants tested display between 17 and 42% residual activities
compared with the wild-type enzyme, whereas the remaining 11
showed no activity. As noted by others, the D556N mutation
(42% activity as compared with the wild-type) introduces a
putative N-glycosylation site into POMGnT1, which cannot be
glycosylated in our E. coli expression system; the introduction
of such a modiﬁcation into the human enzyme might account for
the comparably less severe phenotype observed for this mutation
in vivo [31]. Previously this D556N mutant was assayed from
crude extracts of ﬁbroblasts from patients.
ThemutationC269Y(17%activity)wasobservedinoneallele
of a patient who is a compound heterozygote; the other allele
displaysaframeshiftatbase1077.ThusitappearsthatPOMGnT1
containing this mutation is not able to function properly and,
despite a reasonable degree of activity in vitro, still results in
symptoms; it has been proposed by others that Cys
269 lies within
the so-called stem region, and expression of a full-length form of
this mutant resulted in more-or-less no activity in transfected cell
lysates [33], whereas a soluble form had 10% activity [43]. In
the case of the other patients, the combination of mutant alleles
does not allow us to draw a conclusion as to the in vivo effect
of the speciﬁc mutation which is still compatible with in vitro
activity. The R265H mutation (21% activity) was observed in a
patient together with mutation R311Q (not active in our assay) on
the same allele in addition to mutation R442C (not active) on the
other allele. Although the R265H mutation resulted in residual
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activity, one would expect to observe a severe phenotype in this
patient, due to the other mutation observed [53].
The distribution of the analysed POMGnT1 mutations within
the enzyme was visualized using a model of POMGnT1.
Therefore the crystal structure of GnTI, a homologous
glycosyltransferase also from GT family 13, was used as a
template. Interestingly, the three mutants are shown in the present
study to be active affect side chains (residues 265, 269 and 556)
on the periphery of our homology model. Furthermore, the six
mutations in the region between Arg
311 and Pro
493,w h i c hr e s u l t
in an apparent total loss of activity, correspond to residues also
conserved in human GnTI; indeed, on the basis of homology,
Arg
311 itselfispostulatedtoformakeycontactwiththeO-2aatom
of the α-phosphate of the UDP-GlcNAc donor substrate [41]. On
the other hand, essential residues affected by three mutations of
GnT1 described in the literature (Chinese hamster ovary lec1
and Arabidopsis thaliana cgl) are not represented among the
POMGnT1 variants [55,56]. However, other than the peripheral
location of the three ‘active’ mutations, no absolute disease-
speciﬁc correlation between biochemical data and the position
of a mutation on the protein structure could be determined.
Thus it was concluded that neither genetic data nor structural
modelling would allow us to correlate point mutations with
severity of disease, and that a biochemical analysis is required
in each case.
Possibly signiﬁcant, though, is the location of a predicted
cystine bridge, based on that revealed in the crystal structure
of GnTI, between Cys
421 and Cys
490 of POMGnT1 [41]. The
reduced activity of the rPOMGnT1 C490Y mutant tested in the
present study suggests that Cys–Cys bonding of these residues is
essential for the catalytic function of POMGnT1. As disulﬁde-
bond formation in the cytoplasm of E. coli has been described to
be a rare event [57], the presence of this disulﬁde could explain
the initial difﬁculties of expressing catalytically active wild-type
rPOMGnT1inBL21(DE3)cells.POMGnT1hadpreviouslybeen
expressed in insect and mammalian cell culture by recombinant
methods [22,41], but full-length expression in mammalian cells
has the disadvantage of endogenous GlcNAc transferase activity,
which leads to high background and reduced sensitivity. In
eukaryotic expression systems, the role of cofactor proteins
in vivo that may play a regulatory role cannot be excluded
and, indeed, fukutin may interact intracellularly with POMGnT1
[58]. However, as wild-type POMGnT1 has no putative
N-glycosylation sites, it was a good candidate for expression in
E. coli. When induced at low temperature, the enzyme was well
e x p r e s s e di nas o l u b l ef o r mi nb a c t e r i aa n dw a ss h o w nt ob ef u l l y
active, with Km values similar to those reported for the enzyme
expressedinothersystems[22,31].Theuseofahigher-throughput
soluble expression system also allows us to focus on the effect of
the mutations on catalytic function without considering the role
of the cytosolic, transmembrane or stem regions in intracellular
trafﬁcking.
Previous biochemical data indicate that POMGnT1 transfers
GlcNAc to mannosylated sites on α-DG [41,45]. These in vitro
studieswitheitherMan(α1-)O-benzylorasyntheticglycopeptide
such as NH2-CYAT
•AV-OH (not found in α-DG) and Ac-
AAPT
•PVAAP-NH2 (similar to α-DG region 316–321) were
performed; in the present study, we greatly extended the range of
substrates tested. From the 20 mannopeptide sequences chosen,
only six were shown to be POMGnT1 substrates. It seems that
there is some selectivity of glycosylation by POMGnT1 and
perhapsnotallpotentialglycosylationsitesonα-DGaremodiﬁed
by this enzyme, in agreement with the reports on other O-glycans
found in α-DG [37]. Two recent reports describe either three [59]
or ﬁve [60] O-mannosylated glycan sites in tryptically digested
α-DG peptides isolated from skeletal muscle. These two papers
do not, however, describe the same glycosylation sites; this raises
the question as to exactly how many sites are mannosylated in
vivo, as well as whether there are species differences. Certainly
further synthesis of mannopeptides to ﬁnd potential POMGnT1
glycosylation sites is an essential part of further studies to
uncover the substrate speciﬁcities of enzymes involved in the
O-glycosylation of α-DG.
Kinetic analysis of the wild-type and three active POMGnT1
mutants showed Km values for UDP-GlcNAc between 2 and
3 mM, similar to those reported in the literature using other
methods [31]. Thus these mutations do not seem to affect the
binding to the donor substrate. However, the Km values for
the mannopeptide Ac-ATPT
•PVTAIG-OH varied from ≈6m M
for the wild-type enzyme and D556N mutant, to >25 mM for
the mutants R265H and C269Y. Km values of the two other
acceptor substrates Man(α1-)O-benzyl and the mannopeptide
H-CYA T
•AV-OH reported in the literature were determined
at >15 mM and ≈12 mM respectively [41]. Perhaps because
of using natural substrate sequences, the present kinetic data
comparefavourablywiththosepreviouslyreported,andshowthat
strategies based on glycopeptides sequences derived from protein
substrates can lead to signiﬁcantly improved chemical probes.
In conclusion, the biochemical data obtained from studying
clinical POMGnT1 mutants with synthetic glycopeptides derived
from glycoprotein substrate sequences should be an important
tool to understand the mechanism and severity of disease.
This methodology should also be applicable to other congenital
disorders of glycosylation (such as those caused by mutations
of LARGE [37] which may use similar mannopeptide substrates)
and might help us in future to generate structure–activity models
of the enzyme, by extending our understanding of the molecular
basis of these diseases.
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Biochemical correlation of activity of the α-dystroglycan-modifying
glycosyltransferase POMGnT1 with mutations in muscle-eye-brain disease
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EXPERIMENTAL
Mannopeptide synthesis
General methods
Materialswereobtainedfromcommercialsuppliers(asindicated)
and were used without puriﬁcation. Flash chromatography was
performed using silica gel 60 (35–70 μm, Fluka) and eluant
solvent systems as described. NMR spectra were recorded on
a 400 MHz Bruker spectrometer. NMR chemical shifts are
expressed in p.p.m. using residual solvent peak (CDCl3,7 . 2 7
and 77.0 p.p.m. for
1Ha n d
13C NMR respectively) as a reference.
The coupling constants are reported in Hz using the following
abbreviations: s, singlet; d, doublet; t, triplet; q, quadruplet; qu,
quintet; m, multiplet.
N-(9-ﬂuorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl) serine (1a)
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimid-
ate [1] (3.57 g, 7.24 mmol) and N-Fmoc serine benzyl ester [2]
(3.63 g, 8.70 mmol, 1.20 eq.) were dissolved in 100 ml of dry
dichloromethane and stirred at −30◦C under inert atmosphere.
TMSOTf (trimethylsilyl triﬂuoromethanesulfonate) (178 μl,
0.14 eq.) was diluted in 1 ml of dry dichloromethane, added
dropwise and the reaction was left to stir overnight between −
30◦C and room temperature (23 ◦C). After quenching with
DIPEA (N,N-diisopropylethylamine), the solvent was evaporated
under reduce pressure and the crude mixture was treated with
30 ml of pyridine and 10 ml of acetic anhydride for 3 h. The
pyridine was removed under reduce pressure, the residue diluted
inethylacetateandtheorganicphasewaswashedextensivelywith
a saturated aqueous solution of copper sulfate, water and brine,
and dried over MgSO4. After concentration in vacuo, puriﬁcation
byﬂashchromatographyoversilica(eluant,petroleumether/ethyl
acetate 40:60 then 50:50) afforded 3.63 g (4.85 mmol, 67%)
of N-(9-ﬂuorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-α-
D-mannopyranosyl) serine benzyl ester as a white foam.
NMR measurements:
1H NMR (CDCl3, 400 MHz) δ (p.p.m.)
7.69 (d, J 7.2 Hz, 2 H Ar), 7.56 (d, J 7.2 Hz, 2 H Ar), 7.33–7.19
(m, 9 H Ar), 5.86 (d, J 8.4 Hz, 1 H, NH), 5.23–5.11 (m, 5 H,
H-2, H-3, H-4, CH2Ph), 4.66 (d, J < 1.0 Hz, 1 H, H-1), 4.55 (m,
1H ,H α), 4.33 [d, J 7.2 Hz, 2 H, CH2(Fmoc)], 4.15 [m, 2 H,
CH(Fmoc), H-6a], 4.02 (m, 2 H, H-6b, 1/2 CH2β), 3.92 (m, 2 H,
H-5, 1/2 CH2β), 2.08, 2.00, 1.95, 1.94 (4 s, 12 H, 4 CH3CO).
NMR measurements:
13C NMR (CDCl3, 175 MHz) δ (p.p.m.)
170.6,169.9,169.8,169.7,169.4(5CO),155.9(NHCOO),143.8,
143.7, 141.3, 135.1 (5 C Ar), 128.8, 128.5, 127.8, 127.2, 125.2,
120.1 (13 CH Ar), 98.7 (C-1), 69.9 (CH2β), 69.3, 69.2, 68.8 (C-
Figure S1 SDS/PAGE of partially puriﬁed rPOMGnT1 mutants (a) and the
corresponding anti-His Western blot (b)
The arrows indicate the expressed rPOMGnT1 mutant variant.
2, C-3, C-5), 67.8, 67.4 [CH2Ph, CH2(Fmoc)], 65.9 (C-4), 62.3
(C-6), 54.5 (CHα), 47.1 [CH(Fmoc)], 20.9, 20.7 (4 CH3CO).
The above benzyl ester (1.00 g, 1.34 mmol) was dissolved
in 25 ml of ethyl acetate, 58 mg of 10% Pd-C was added
and the reaction was stirred for 16 h under an atmosphere of
H2. The catalyst was ﬁltered off over a pad of celite and the
solventwasremovedunderreducedpressure.Puriﬁcationbyﬂash
chromatography over silica (eluant, dichloromethane/methanol
98:2 then 90:10) yielded 660 mg (1.00 mmol, 75%)o f1 aa sa
white foam.
NMR measurements:
1H NMR (CDCl3, 400 MHz) δ (p.p.m.)
7.68 (d, J 7.2 Hz, 2 H Ar), 7.54 (d, J 7.2 Hz, 2 H Ar), 7.32 (t, J
7.6 Hz, 2 H Ar), 7.23 (t, J 7.6 Hz, 2 H Ar), 6.52 (d, J 8.0 Hz, 1
H, NH), 5.39 (dd, J 3.6, 10.0 Hz, 1 H, H-3), 5.20 (m, 1 H, H-2),
5.18 (t, J 10.0 Hz, H-4), 4.80 (d, J < 1.0 Hz, 1 H, H-1), 4.63 (m,
1H ,Hα), 4.35 (dd, J 7.6, 10.4 Hz, 1/2 CH2β), 4.24 (dd, J 7.6,
10.4 Hz, 1/2 CH2β), 4.20–4.11 [m, 2 H, CH(Fmoc), H-6a], 4.00
[m, 4 H, H-5, H-6b, CH2(Fmoc)], 2.09, 1.99, 1.95, 1.90 (4 s, 12
H, 4 CH3CO).
NMR measurements:
13C NMR (CDCl3, 175 MHz) δ (p.p.m.)
171.7,170.8,170.2,169.9(4CO),156.0(NHCOO),143.8,143.7,
141.3 (4 C Ar), 127.8, 127.1, 125.2, 120.0 (4 CH Ar), 98.1 (C-1),
69.4(C-2,C-3,C-5),68.9[CH2(Fmoc)],67.3(CH2β),66.1(C-4),
62.3 (C-6), 54.0 (CHα), 47.1 [CH(Fmoc)], 21.2, 21.0, 20.9, 20.7
(4 CH3CO).
1 To whom correspondence should be addressed (email sabine.ﬂitsch@manchester.ac.uk).
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Table S1 Primer pairs for the introduction of mutations into POMGnT1
The single point mutations are shown in bold and underlined.
Mutation Position Forward primer Reverse primer
S198R 594 5 -GGCTCTGCTGAGGAGCCTGGGCAGGCAGGCTGGCCCTGCCCTGGGCTGGA-3  5 -TCCAGCCCAGGGCAGGGCCAGCCTGCCTGCCCAGGCTCCTCAGCAGAGCC-3 
E223K 667 5 -ACGAAAAGGAGGTCCTGTCTTCGGGAAGAAACATTCTAAATCACCTGCCC-3  5 -GGGCAGGTGATTTAGAATGTTTCTTCCCGAAGACAGGACCTCCTTTTCGT-3 
R265H 794 5 -CAGACACAGAGCTGAACCGTCGCCACCGGCGCTTCTGCAGCAAAGTTGAG-3  5 -CTCAACTTTGCTGCAGAAGCGCCGGTGGCGACGGTTCAGCTCTGTGTCTG-3 
C269Y 806 5 -CTGAACCGTCGCCGCCGGCGCTTCTACAGCAAAGTTGAGGGCTATGGAAG-3  5 -CTTCCATAGCCCTCAACTTTGCTGTAGAAGCGCCGGCGGCGACGGTTCAG-3 
R311Q 932 5 -CTGTGGCTGTCATTGCAGGGAACCAACCCAATTACCTGTACAGGATGCTG-3  5 -CAGCATCCTGTACAGGTAATTGGGTTGGTTCCCTGCAATGACAGCCACAG-3 
W425S 974 5 -ACAGCCTGTACTGCATCTCTGCCTCGAATGACCAGGGGTATGAACACACG-3  5 -CGTGTGTTCATACCCCTGGTCATTCGAGGCAGAGATGCAGTACAGGCTGT-3 
R442C 1324 5 -CTGAGGACCCAGCACTACTGTACTGTGTGGAGACCATGCCTGGGCTGGGC-3  5 -GCCCAGCCCAGGCATGGTCTCCACACAGTACAGTAGTGCTGGGTCCTCAG-3 
R442H 1324 5 -CTGAGGACCCAGCACTACTGTACCATGTGGAGACCATGCCTGGGCTGGGC-3  5 -GCCCAGCCCAGGCATGGTCTCCACATGGTACAGTAGTGCTGGGTCCTCAG-3 
C490Y 1469 5 -CCTGAACAACGCCGGGGCCGAGAGTACATCATCCCTGACGTTTCCCGATC-3  5 -GATCGGGAAACGTCAGGGATGATGTACTCTCGGCCCCGGCGTTGTTCAGG-3 
P493R 1478 5 -CGCCGGGGCCGAGAGTGCATCATCCGTGACGTTTCCCGATCCTACCACTT-3  5 -AAGTGGTAGGATCGGGAAACGTCACGGATGATGCACTCTCGGCCCCGGCG-3 
R580X 1738 5 -GGGCCACACCTACGTGGCCTTTATTTGAATGGAGAAAGATGATGACTTCA-3  5 -TGAAGTCATCATCTTTCTCCATTCAAATAAAGGCCACGTAGGTGTGGCCC-3 
W590X 1769 5 -AGAAAGATGATGACTTCACCACCTAGACCCAGCTTGCCAAGTGCCTCCAT-3  5 -ATGGAGGCACTTGGCAAGCTGGGTCTAGGTGGTGAAGTCATCATCTTTCT-3 
D556N 1666 5 -CTGCTCAGTGAGGCTGAGGTTCTGAACCACAGCAAGAACCCTTGTGAAGA-3  5 -TCTTCACAAGGGTTCTTGCTGTGGTTCAGAACCTCAGCCTCACTGAGCAG-3 
R605H 1814 5 -CTCCATATCTGGGACCTGGATGTGCATGGCAACCATCGGGGCCTGTGGAG-3  5 -CTCCACAGGCCCCGATGGTTGCCATGCACATCCAGGTCCCAGATATGGAG-3 
Figure S2 MALDI–TOF spectra showing increased mass corresponding to
the transfer of a GlcNAc
N-(9-ﬂuorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl) threonine (1b)
Glycosylation of N-Fmoc threonine benzyl ester (1.02 g, 2.44
mmol,1.20eq.)with2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl
trichloroacetimidate (1.00 g, 2.03 mmol) was performed
following the procedure described for the synthesis of 1a.
Puriﬁcation by ﬂash chromatography over silica (eluant,
petroleum ether/ethyl acetate 30:70 then 40:60) afforded 957 mg
(1.26 mmol, 62%)o fN-(9-ﬂuorenylmethoxycarbonyl)-O-
(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl) threonine benzyl
ester as a white foam.
NMR measurements:
1H NMR (CDCl3, 400 MHz) δ (p.p.m.)
7.80 (d, J 7.6 Hz, 2 H, H Ar), 7.67 (d, J 7 . 2H z ,2H ,H
Ar), 7.45–7.33 (m, 9 H Ar), 5.61 (d, J 9.6 Hz, 1 H, NH),
5.34 (dd, J 3.2, 10.0 Hz, 1 H, H-3), 5.30 (t, J 1 0 . 0H z ,1H ,
H-4), 5.27 (q, J 1 2 . 4H z ,2H ,C H 2Ph), 5.10 (m, 1 H, H-2),
4.88 (d, J < 1.0 Hz, 1 H, H-1), 4.54 (dd, J 9.6, 2.0 Hz, 1 H,
Hα), 4.49–4.38 [m, 3 H, Hβ,C H 2(Fmoc)], 4.28 [m, 2 H, H-
6a, CH(Fmoc)], 4.14 (m, 1 H, H-6a), 4.07 (m, 1 H, H-5), 2.18,
2.11, 2.09, 2.05 (4 s, 12 H, 4 CH3CO), 1.35 (d, J 6 . 4H z ,1H ,
CH3).
NMR measurements:
13C NMR (CDCl3, 175 MHz) δ (p.p.m.)
171.0, 170.3, 170.2 (5 CO), 157.1 (NHCOO), 144.3, 144.1,
141.7, 135.4 (4 C Ar), 129.1, 129.0, 128.9, 128.1, 127.5, 120.4
(13 CH Ar), 99.2 (C-1), 78.0 (CHβ), 70.1 (C-2), 69.5, 69.1
(C-3, C-5), 68.3, 67.9 [CH2Ph, CH2(Fmoc)], 66.7 (C-4), 62.9
(C-6), 59.2 (CHα), 47.5 [CH(Fmoc)], 21.4, 21.2 (4 CH3CO),
18.4 (CH3).
The above benzyl ester (957 mg, 1.26 mmol) was dissolved
in 25 ml of ethyl acetate, 60 mg of 10% Pd-C was added
and the reaction was stirred for 16 h under an atmosphere of
H2. The catalyst was ﬁltered off over a pad of celite and the
solventwasremovedunderreducedpressure.Puriﬁcationbyﬂash
chromatography over silica (eluant, dichloromethane/methanol
98:2 then 95:5) yielded 785 mg (1.17 mmol, 93%)o f1 ba sa
white foam.
NMR measurements:
1H NMR (CDCl3, 400 MHz) δ (p.p.m.)
7.78 (d, J 7.6 Hz, 2 H, H Ar), 7.66 (t, J 7.2 Hz, 2 H, H Ar),
7.42–7.33 (m, 4 H Ar), 6.04 (d, J 9.2 Hz, 1 H, NH), 5.35 (dd, J
3.2, 10.0 Hz, 1 H, H-3), 5.28 (t, J 10.0 Hz, 1 H, H-4), 5.12 (dd, J
< 1.0 Hz, J = 3.2 Hz, 1 H, H-2), 5.00 (d, J < 1 Hz, 1 H, H-1),
4.52–4.43 (m, 2 H, Hα,H β), 4.45–4.36 [m, 2 H, CH2(Fmoc)],
4.27 [m, 2 H, H-6a, CH(Fmoc)], 4.13 (m, 2 H, H-5, H-6b), 2.12,
2.09, 2.06, 2.01 (4 s, 12 H, 4 CH3CO), 1.33 (d, J 6 . 4H z ,1H ,
CH3).
NMR measurements:
13C NMR (CDCl3, 175 MHz) δ (p.p.m.)
173.0, 170.7, 170.6, 170.6, 169.8 (5 CO), 156.8 (NHCOO),
143.9, 143.8, 141.3 (3 C Ar), 127.7, 127.1, 125.6, 120.0 (8
CH Ar), 98.8 (C-1), 77.9 (CHβ), 69.8 (C-2), 69.0, 68.9 (C-3,
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Table S2 Protein concentrations of the expressed mutant rPOMGnT1
proteins
Mutation Protein concentration ( μg/ml)
Wild-type 189+ −36
S198R 89+ −20
E223K 119+ −19
C269Y 109+ −8
R265H 121+ −28
R311Q 85+ −16
W425S 118+ −22
R442C 99+ −23
R442H 63+ −24
C490Y 97+ −40
P493R 111+ −33
R580X 93+ −19
W590X 52+ −20
D556N 158+ −30
R605H 252+ −49
C-5), 67.3 [CH2(Fmoc)], 66.2 (C-4), 62.6 (C-6), 58.7 (CHα),
47,2 [CH(Fmoc)], 21.1, 20.9, 20.8, 20.7 (4 CH3CO), 18.1 (CH3).
Peptide synthesis
Peptide synthesis was performed under standard Fmoc-based
SPSS conditions using a CEM Liberty® peptide synthesizer.
Commercial Fmoc-protected amino acids (5 eq.), PyBOP
(benzotriazol-1-yl-oxytripyrrolidino phosphonium hexaﬂuoro-
phosphate, 5 eq.) and DIPEA (N,N-diisopropylethylamine, 10
eq.) were used for the coupling steps, and piperidine (20%
solution in DMF) for the Fmoc deprotection steps. In order to
minimize acyl migration from the mannose on to the peptide
N-terminus, coupling of the glycosylated serine 1a or threonine
1b (1 eq.) was performed manually using 1 eq. of PyBOP and
1 eq. of 2,4,6-trimethylpyridine at room temperature for 3 h.
Aftercompletion,theresin-boundpeptidewasthoroughlywashed
with DMF (dimethylformamide), DMF-MeOH (DMF-methanol)
(1:1) and DCM (dichloromethane), and cleaved from the resin
with triﬂuoroacetic acid/triisopropylsilane/water (95:2.5:2.5, by
vol.).Precipitationincoldether,centrifugationandremovalofthe
solventaffordedthedesiredpeptideasawhitesolid.Deacetylation
of the mannosyl moiety was performed by dissolving the peptide
in dry methanol and adding a freshly prepared solution of sodium
methoxide in methanol until pH 10. After stirring for 2 h, the
reaction mixture was neutralized with 1 M HCl, the solvent was
removed in vacuo and the residue was dissolved in water and
freeze-dried to afford the desired peptide as a white solid, which
was then used without further puriﬁcation.
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